Advances in the Immunogenic Design of HIV-1 Vaccine / 病毒学报
Chinese Journal of Virology
;
(6): 88-92, 2016.
Article
in Chinese
| WPRIM
| ID: wpr-296212
ABSTRACT
A safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is expected to have a considerable impact on elimination of acquired immune deficiency syndrome. Despite decades of effort, an effective vaccine against HIV-1 remains elusive. In recent years, the Thai HIV Vaccine Efficacy Trial (known as RV144) showed a reduction in HIV-1 acquisition by 31%, but this agent could not delay disease progression in vaccinated individuals. Clinical analyses of experimental data and experiments in vitro have revealed two main types of immunogen design:
induction of broad-spectrum neutralizing antibody (bNAb) and cytotoxic T lymphocyte (CTL) responses. bNAb can prevent or reduce acquisition of infection, and its main immunogens are virus-like particles, natural envelope trimers and stable bNAb epitopes. An effective CTL response can slow-down viral infection, and its main immunogens are "mosaic" vaccines, "conserved immunogens", and the "fitness landscape" of HIV-1 proteins. This review summarizes the strategies as well as progress in the design and testing of HIV-1 immunogens to elicit bNAb and CTL responses.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Virology
/
Drug Design
/
HIV Antibodies
/
HIV Infections
/
HIV-1
/
AIDS Vaccines
/
Allergy and Immunology
/
Genetics
Limits:
Animals
/
Humans
Language:
Chinese
Journal:
Chinese Journal of Virology
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS